KA vs. PCSA, YMTX, AIMD, PTIX, KTRA, HILS, HOTH, LIXT, IBIO, and XBIO
Should you be buying Kineta stock or one of its competitors? The main competitors of Kineta include Processa Pharmaceuticals (PCSA), Yumanity Therapeutics (YMTX), Ainos (AIMD), Protagenic Therapeutics (PTIX), Kintara Therapeutics (KTRA), Hillstream BioPharma (HILS), Hoth Therapeutics (HOTH), Lixte Biotechnology (LIXT), iBio (IBIO), and Xenetic Biosciences (XBIO). These companies are all part of the "pharmaceutical preparations" industry.
Processa Pharmaceuticals (NASDAQ:PCSA) and Kineta (NASDAQ:KA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.
91.9% of Processa Pharmaceuticals shares are held by institutional investors. Comparatively, 30.3% of Kineta shares are held by institutional investors. 22.2% of Processa Pharmaceuticals shares are held by company insiders. Comparatively, 29.8% of Kineta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Kineta's return on equity of -141.42% beat Processa Pharmaceuticals' return on equity.
Processa Pharmaceuticals has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Kineta has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500.
Processa Pharmaceuticals received 6 more outperform votes than Kineta when rated by MarketBeat users. However, 100.00% of users gave Kineta an outperform vote while only 47.37% of users gave Processa Pharmaceuticals an outperform vote.
Processa Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 213.73%. Kineta has a consensus target price of $8.00, indicating a potential upside of 1,274.10%. Given Processa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kineta is more favorable than Processa Pharmaceuticals.
Processa Pharmaceuticals has higher earnings, but lower revenue than Kineta. Kineta is trading at a lower price-to-earnings ratio than Processa Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Processa Pharmaceuticals had 1 more articles in the media than Kineta. MarketBeat recorded 1 mentions for Processa Pharmaceuticals and 0 mentions for Kineta. Kineta's average media sentiment score of 0.63 beat Processa Pharmaceuticals' score of 0.00 indicating that Processa Pharmaceuticals is being referred to more favorably in the media.
Summary
Processa Pharmaceuticals beats Kineta on 9 of the 16 factors compared between the two stocks.
Get Kineta News Delivered to You Automatically
Sign up to receive the latest news and ratings for KA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
